BeiGene's Stock Is Trading Higher As Brukinsa Drug On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies

  • BeiGene Ltd BGNE announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa (zanubrutinib) against Johnson & Johnson's JNJ Imbruvica (ibrutinib) in adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
  • The data is based on 415 of 652 patients followed for a minimum of 12 months. The planned final analysis is expected in 2022.
  • Brukinsa met the primary endpoint of the trial, demonstrating non-inferiority in objective response rate (ORR) vs. ibrutinib by investigator assessment and a numerically higher ORR but not statistically significant improvement by the independent review committee.
  • The trial also met a prespecified secondary endpoint related to safety, and Brukinsa demonstrated a statistically significant lower risk of atrial fibrillation or flutter versus ibrutinib.
  • BeiGene plans to present these data at an upcoming major medical conference.
  • Price Action: BGNE shares are up 9.2% at $353.25 during market trading hours on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralblood cancerBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!